Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous cultured immature erythroblast implantation for severe limb ischemia
ISRCTN66803682Phase 2Completed
- Sponsor
- Niigata University Medical and Dental Hospital
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erythropoietin in arteriosclerosis obliterans, Buerger disease (TAO) and arteritis, sponsored by Niigata University Medical and Dental Hospital. Primary endpoints: Ankle-Brachial Index improvement, Transcutaneous oxygen pressure improvement and 5 more. Started Nov 2007; status: completed.
02
Drugs
erythropoietin
03
Conditions
arteriosclerosis obliteransBuerger disease (TAO)arteritis
Beyond the preview
Go deeper on ISRCTN66803682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66803682.